key: cord-1002255-82dpzxs8
authors: Yadav, Anjali; Rastogi, Neha; Upasana, K.; Arora, Sunisha; Thakkar, Dhwanee; Yadav, Satya Prakash
title: Milder COVID-19 in children with inborn errors of immunity
date: 2022-05-07
journal: Pediatric Hematology Oncology Journal
DOI: 10.1016/j.phoj.2022.05.002
sha: f88b0308887bc8656146b5e45d5a1747f5369848
doc_id: 1002255
cord_uid: 82dpzxs8

nan

To the editor: Inborn errors of immunity (IEI) refers to a group of genetic disorders with either deficiency or dysregulation in humoral, cellular or innate immunity. It is postulated that Coronavirus disease 2019 in children with IEI will have different outcomes than general population due to their altered/ dysregulated immune system. The mortality associated with COVID-19 is mostly due to dysregulated inflammatory response rather than the direct viral injury, or viral replication itself (1) . COVID-19, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) has posed a significant threat to global public health and patients with comorbidities are at higher risk of complications (2) . We have total of 31 children with IEI (Wiskott-Aldrich-5, Hemophagocytic lympho-histiocytosis-6, DOCK-8 deficiency-1, Common variable immune deficiency-1, Chronic granulomatous disease-1, Severe combined immunedeficiency-3, Heme-Oxygenenase-1 deficiency-3, Chediak-Higashi Syndrome-1, Autoimmune lymphoproliferative syndrome-4, Agammaglobulinemia-4, GATA2 deficiency- He recovered completely with supportive care at home within a week. At present, he is 6months post COVID-19 infection and is doing fine. He continued oral sirolimus throughout this illness. He was on tab sirolimus 1 mg orally twice daily and levels were not checked.

However, he had normal renal functions and serum triglyceride levels.

Although exact pathogenesis of COVID-19 is still elusive, most studies suggest that it is due to immune dysregulation & hyperinflammatory response to virus (1). Thus, its course in IEI is very unpredictable. Previous studies suggested that T-cell immunity is more important in COVID-19 to clear the infection (3) . It was also postulated that B-cell immunity does not have major role in viral clearance but leads to hyperinflammatory response which further increase J o u r n a l P r e -p r o o f morbidity and mortality due to COVID-19. X-linked agammaglobulinemia is considered advantageous IEI as B-cell deficiency may prevent inflammation, thus limiting major devastating sequelae of the disease (5) . This hypothesis of antibody defects leading to mild COVID-19 course is supported by few other studies (4, 5) . Agammaglobulinemia patients who lack B lymphocytes showed milder course of disease and did not require any ICU care as compared to patients with common variable immunodeficiency (CVID) who are characterized by dysfunctional B cells and had severe disease (6,7). Meyts et al studied 94 patients of IEI with COVID-19 and reported that >30% had mild disease and mortality rate was 10% and it was mainly among patients with other co-morbidities like heart and kidney diseases (8) . They Though complete B cell deficiency reduces allograft inflammation, B cell deficiency are well known for inflammation also. XLA have symptoms that are consistent with a diagnosis of inflammatory parenchymal disease, arthritis, inflammatory bowel disease or other inflammatory condition (10) . Contrary to previous studies, others have reported poorer outcomes among patients with IEI compared to the general population especially among patients with combined immunodeficiency and immune dysregulation, although whether SARS-CoV-2 infection contributed directly or indirectly to any of those deaths was unclear (11, 12) . Both our cases showed milder course and did not require any hospitalization. However, it is very difficult to draw a conclusion from just two cases and to state that IEI are actually J o u r n a l P r e -p r o o f protective against severe COVID-19 disease is not prudent. It is quite possible that various IEI can have different outcomes with COVID-19 infection due to involvement of different immune pathways. Various IEI may behave differently to different microbes because of various types of immunological status of patients with different IEI (humoral, cellular, innate). Likewise, ALPS and XLA are completely different spectrum of IEI. Further studies needed for better understanding of impact of COVID-19 on IEI.

Consent -Informed consent was obtained from parents of both children included in this report.

Disclosure -All authors have nothing to declare.

Immune responses during COVID-19 infection

Outbreak of COVID-19: An emerging global pandemic threat

Immune-epidemiological parameters of the novel coronavirus -a perspective

Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?

Minor Clinical Impact of COVID-19 Pandemic on Patients with Primary Immunodeficiency in Israel

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

COVID-19 and primary immunodeficiency: one-year experience

Autoimmunity and inflammation in X-linked agammaglobulinemia

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency